Literature DB >> 15146015

A dystonic syndrome associated with anti-basal ganglia antibodies.

M J Edwards1, R C Dale, A J Church, G Giovannoni, K P Bhatia.   

Abstract

Anti-basal ganglia antibodies (ABGA) have been associated with movement disorders (usually tics and chorea) and psychiatric disturbance in children. This report describes five adult and adolescent patients (one male, four females; mean age of onset, 16 years (range, 13-35)) who presented subacutely with a clinical syndrome dominated by dystonia and had ABGA binding to antigens of similar molecular weights to those seen in Sydenham's chorea. Three patients had a clear history of respiratory infection before the onset of their symptoms. Three patients received immunosuppressive treatment, with three showing a notable reduction in symptoms. It is hypothesised that dystonia in adults or adolescents may be part of the clinical spectrum of the post-infectious syndrome associated with ABGA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15146015      PMCID: PMC1739048          DOI: 10.1136/jnnp.2002.009043

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  3 in total

1.  Idiopathic progressive chorea: misnomer or still reality? A case with neuropathological disconfirmation.

Authors:  Lucio Tremolizzo; Giorgio Giaccone; Fabrizio Tagliavini; Carlo Ferrarese; Ildebrando Appollonio
Journal:  Neurol Sci       Date:  2014-03-17       Impact factor: 3.307

2.  Gluten Ataxia and Post-Streptococcal Central Nervous System Syndromes: Emerging Immune-mediated Disorders of the Central Nervous System?

Authors:  Adrian Wills; Russell Dale; Gavin Giovannoni
Journal:  Curr Treat Options Neurol       Date:  2005-05       Impact factor: 3.972

3.  Does treatment of the laryngeal mucosa reduce dystonic symptoms? A prospective clinical cohort study of mannose binding lectin and other immunological parameters with diagnostic use of phonatory function studies.

Authors:  Mette Pedersen; Martin Eeg
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-05       Impact factor: 2.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.